Abstract: A pharmaceutical composition containing 3-(2,2,2-trimethylhydrazinium)propionate and .gamma.-butyrobetaine with a pharmaceutically acceptable carrier for the treatment of cardiovascular diseases is disclosed. The composition may be for oral, parenteral, subcutaneous or rectal administration and exhibits low toxicity and a wide interval of therapeutic action safety.